Cell & Gene Therapy
Once considered almost science fiction in medicine, personalised medicine is increasingly becoming a day-to-day reality for many patients. As innovative pharma continues to invest heavily in high-risk frontier research involving stem cells and the harnessing of a patient’s own immune system to attack the onset of a disease, a brave new world of potentially curative treatment possibilities is unfolding. This has become most evident in fields like oncology where expensive, yet thoroughly transformative CAR-T therapies are displacing classic treatments and offering newfound hope to patients where previously there was none.
Stefan Hendriks - Global Head Cell & Gene, Novartis Oncology
Stefan Hendriks, Global Head of Novartis Oncology’s Cell & Gene division outlines the company’s progression to becoming the global leader in cell and gene therapies, the strategy he has outlined for the business, and the key issues of manufacturing and access.
Funding the Cell & Gene Therapy Boom
The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the history of the pharmaceuticals industry. Not only do innovative therapies such as CAR-T herald a shift towards genuinely individualized medicine and an exciting new front in the war against cancer, but the pace of technological advancement in such a complex domain has also been…
Reconsidering CGT Manufacturing
Advances in cell and gene therapies (CGT) are credited with thoroughly transforming medicinal science and creating an inflection point in the ability to treat and potentially cure many intractable illnesses. To date, however, accessibility to many of these game changing technologies remains limited, often due to high upfront sticker-prices and the formidable challenges associated with scalability.
The Collaborative Spirit of Cell & Gene
One of the more intriguing aspects about the new wave of cell and gene therapies (CGT) coming onstream is that they are not just technologically innovative in terms of the sheer novelty of the medical science, but they are also serving to upend the traditional operating model of the pharma industry and break down longstanding silos, barriers and partitions.
RWE: Unlocking the full potential of Cell & Gene
Emerging cell and gene therapies herald immense clinical value for patients, society, and healthcare systems: carrying the potential to offer life-changing solutions for people with few or no alternative treatments. Given the limited amount of long-term…
eBook
Cell & Gene Therapy
Once considered almost science fiction in medicine, personalised medicine is increasingly becoming a day-to-day reality for many patients. As innovative pharma continues to invest heavily in high-risk frontier research involving stem cells and the harnessing of a patient’s own immune system to attack the onset of a disease, a brave new world of potentially curative treatment possibilities is unfolding…
Top Interviews on PharmaBoardroom
See more about Cell & Gene Therapy
Contact us
+44 20 7867 3717 info@gamma.pharma.kalyna.dev
For media inquiries, please contact: media@gamma.pharma.kalyna.dev
Address
PharmaBoardroom Limited Lynton House, 7-12, Tavistock Square, London, United Kingdom, WC1H 9LT
